HOME >> MEDICINE >> NEWS
Biomolecule studied for medical uses

DURHAM, N.C. -- Duke University Chemistry Department researchers are creating unique polymers out of naturally occurring building blocks that don't provoke immune reactions and in some cases also biodegrade in the body. The tree-like, globular-shaped substances are being evaluated for a variety of medical uses.

Called biodendrimers, these structures are prepared by systematically reacting acids with alcohols to form what chemists call "esters." The results are branching molecular chains with finger-like ends that can form sticky and tenacious links with other substances.

These characteristics make them "ideal candidates for medical and tissue engineering applications," said Mark Grinstaff, the assistant chemistry professor who heads the Duke team. One potential application, which Duke Medical Center eye researchers are beginning to test, is a glue that could "close a wound and then be dissolved as new tissue grows in to repair the wound site," he added in an interview.

"It could really potentially change the way we do corneal surgery," added Dr. Terry Kim, associate director of the Corneal and Refractive Surgery Service at the Duke Eye Center and a medical center assistant professor of ophthalmology.

Another possibility, which biomedical researchers at Duke's Pratt School of Engineering have also started investigating, would be using such biodendrimers as scaffolding to help induce cells to repair damaged human joints.

"Biodendrimers appear to interact with cells in completely novel manners," said Lori Setton, assistant professor and Harold L. Yoh Faculty Scholar in the Pratt School's Department of Biomedical Engineering. Because of its promise, Grinstaff's research just received $250,000 in funding from the Johnson & Johnson Focused Giving program, established to stimulate exploration in medical science. Other funding sources include the Pew, Sloan and Dreyfus foundations.

In a spring 2001 issue of the Journal of the Americ
'"/>

Contact: Monte Basgall
monte.basgall@duke.edu
919-681-8057
Duke University
30-Aug-2001


Page: 1 2 3 4

Related medicine news :

1. Technology that could double the effectiveness of cancer drugs studied at Yale
2. New global trials help to make FOSRENOL(R) the most extensively studied modern phosphate binder
3. Mind-body connection in placebo surgery trial studied by University of Denver researcher
4. Possible brain cancer-air pollution link to be studied
5. Investigational mesh jackets studied as an experimental therapy for heart failure
6. Venlafaxine XR, first SNRI studied for social anxiety disorder
7. New pathway for treating hypertension-related kidney failure studied
8. Intensification therapy studied in head and neck cancer
9. Chronic disease: the overlooked & understudied epidemic
10. Advertising by academic medical centers may risk eroding public trust, says study
11. NIH state-of-the-science panel calls for demedicalization of menopause

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Biomolecule studied for medical uses

(Date:7/30/2015)... ... 2015 , ... In an effort to provide the twenty four hour continuous ... in his practice. , The decision will also allow him to spend more time ... transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ... takes a look at small, medium, and large businesses making an impact in ... the business review and shared with viewers how DevExpress has provided software development ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Institute Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the ... on the front lines and throughout the experience movement, and provide information and ...
(Date:7/30/2015)... Beach, California (PRWEB) , ... July 30, 2015 ... ... and services, announced today that the latest issue of Inclusive™ magazine, its multimedia ... digital platforms. The digital edition of the new issue, Volume 6, Issue 2, ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... -- Big Cloud Analytics, Inc. (BCA), a leading provider ... working with Intel Corporation to showcase Internet of ... Healthcare Technology Alliance. The recently formed alliance is ... technology companies and academic institutions. Its purpose is ... in rapidly evolving and growing areas of health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
Cached News: